Short answer
Tango Therapeutics, Inc. (TNGX) filed an 8-K current report with the SEC on October 23, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). Updated Phase 1/2 trial results for vopimetostat combined with Revolution Medicines’ RAS(ON) inhibitors.
Tango Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Updated Phase 1/2 trial results for vopimetostat combined with Revolution Medicines’ RAS(ON) inhibitors
- Results cover an ongoing clinical program, making emerging efficacy and safety data material to TNGX valuation
- Detailed findings available in Exhibit 99.1 press release and Exhibit 99.2 presentation
Item 8.01 · Other Events
- Daraxonrasib combination showed 82% ORR and 88% 9-month PFS in 22 efficacy-evaluable second- or third-line PDAC patients
- Dose level 1 safety generally manageable, but 40% Grade 3 TRAEs and dose level 2 produced 3 DLTs in 2 patients
- Zoldonrasib combination delivered 54% ORR, 61% 9-month PFS, and 97% DCR across 35 efficacy-evaluable patients
- FDA discussions support a planned randomized registrational trial versus standard chemotherapy in first-line MTAP-deleted PDAC, targeted for first half 2027
- Strategic reprioritization shifts resources to PRMT5 programs, halting selected research and reducing workforce approximately 14%
Item EX-99.1 · Exhibit EX-99.1
- Phase 1/2 PDAC data: 82% ORR, 88% 9-month PFS, and 100% disease control in 22 efficacy-evaluable patients
- Planned global Phase 3 in front-line MTAP-deleted PDAC targets 1H 2027, with ORR and PFS primary endpoints
- Proposed regimen: vopimetostat 200 mg daily plus daraxonrasib 100 mg daily versus standard chemotherapy
- Dose level 1 showed 40% Grade 3 TRAEs and 20% dose reductions, while dose level 2 produced 3 DLTs in 2 patients
- Zoldonrasib combination delivered 54% ORR and 61% 9-month PFS across 35 efficacy-evaluable patients
Item EX-99.2 · Exhibit EX-99.2
- PDAC update highlights 82% ORR and 88% 9-month PFS for vopimetostat plus daraxonrasib in MTAP-deleted disease
- Phase 3 first-line trial planned for 1H 2027, targeting 484 patients with dual ORR and PFS primary endpoints
- Dose level 1 showed no Grade 3 rash or stomatitis, no Grade 4 or 5 treatment-related adverse events
- $1.0B cash and investments as of June 30, 2026, expected to fund PDAC late-stage development and ongoing programs
- Expansion strategy targets MTAP-wild-type PDAC, NSCLC, and other cancers through RAS-inhibitor combinations
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Tango Therapeutics, Inc. 8-K filings
Get the next TNGX 8-K as it lands
Follow TNGX for push alerts, or ask the research agent what this filing means.